Skip to main content

157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Publication ,  Conference
Oya, M; Armstrong, AJ; Thiery-Vuillemin, A; Shore, N; Procopio, G; Arslan, Ç; Mehra, N; Parnis, F; Brown, E; Constans Schlurmann, F; Joung, JY ...
Published in: Annals of Oncology
November 2022

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

November 2022

Volume

33

Start / End Page

S1495 / S1495

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Oya, M., Armstrong, A. J., Thiery-Vuillemin, A., Shore, N., Procopio, G., Arslan, Ç., … Saad, F. (2022). 157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In Annals of Oncology (Vol. 33, pp. S1495–S1495). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.10.194
Oya, M., A. J. Armstrong, A. Thiery-Vuillemin, N. Shore, G. Procopio, Ç. Arslan, N. Mehra, et al. “157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In Annals of Oncology, 33:S1495–S1495. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.10.194.
Oya M, Armstrong AJ, Thiery-Vuillemin A, Shore N, Procopio G, Arslan Ç, Mehra N, Parnis F, Brown E, Constans Schlurmann F, Joung JY, Sugimoto M, Sartor O, Liu Y-Z, Poehlein CH, Desai C, Del Rosario PMD, Clarke N, Saad F. 157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. Elsevier BV; 2022. p. S1495–S1495.

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

November 2022

Volume

33

Start / End Page

S1495 / S1495

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis